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Classification) group of drugs was prescribed. Our composite health index, CHI, 
is a coverage-weighted average of the separate indices we construct for persons 
covered by each community drug scheme in each region. Results: Respiratory 
health status varies most across Irish regions but Cardiovascular, Central Nervous 
System and ‘Other’ health conditions have higher CHI weights and contribute more 
to overall regional health disparities. The Midlands region had the poorest health 
status in 2010 (8% below the national average); the Eastern region had the best 
(6% above average), followed closely by the Mid-West. The Mid-West has a better 
health status than the Midlands despite having lower income and a larger elderly 
population share. The health status of the Eastern region is just 2% higher than the 
Mid-West even though its income is 6% higher and the percentage of its population 
aged over 65 is 1.8 percentage points lower. Simple economic and demographic 
variables - mean income and the elderly population share – correlate well with 
health status. ConClusions: Our index maps significant regional disparities and 
paves the way for complementary epidemiological studies to trace their underlying 
lifestyle and medical causes and inform regional health policy.
HealtH Care Use & PoliCy stUdies – Prescribing Behavior & treatment 
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FeasiBility oF MediCines review to redUCe Potentially inaPProPriate 
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Controlled trial
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objeCtives: Potentially inappropriate medicines (PIMs) can result in increased 
morbidity, adverse drug events and hospitalizations. Polypharmacy is the strongest 
predictor of PIMs,the prevalence of which was 36% in 2007 in those aged ≥ 70 years 
, with an associated expenditure of over € 45 million. Medicines review may have 
the potential to improve patient outcomes and reduce prescribing costs. This study 
aims to assess the feasibility of introducing medicines review to reduce PIMs in older 
patients. Methods: OPTI-SCRIPT is a cluster randomized controlled trial (RCT), that 
aims to assess the effectiveness of a complex intervention incorporating academic 
detailing, a medicines review with web-based pharmaceutical treatment algorithms 
that provide recommended alternative treatments, and tailored patient information 
leaflets in reducing PIMs. A qualitative evaluation is being conducted to determine the 
feasibility and acceptability of the intervention. Results: Twenty-one GP practices 
(response rate 32.3%) participated. Identifying patients with a PIM required consider-
able time and expertise. Practices screened all patients aged ≥ 70 years to identify 
those suitable to participate. A pharmacist reviewed their repeat medications, identi-
fying patients with a PIM who were then invited to participate. Despite being offered 
a once off review of their current prescriptions with their GP, only 37.4% (196) agreed 
to participate. Preliminary qualitative findings indicate that intervention group GPs 
valued the review process as an opportunity to reflect on their prescribing practice. 
Some GPs highlighted that conducting routine structured reviews with older patients 
wouldn’t be feasible due to the time, resources and funding available to them cur-
rently in primary care. Participating patients placed a high value on their medicines 
review. ConClusions: Preliminary findings illustrate that implementing a system of 
structured reivews for older patients with a PIM is challenging. However, participating 
GPs and older patients saw the value of conducting medicines reviews, but formal 
resourcing of such services would need to be considered.
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objeCtives: The present study aimed to determine the proportion of physicians 
in Japan who use clinical practice guidelines, as well as factors influencing this 
choice. Methods: We conducted an on-line cross-sectional survey throughout 
Japan on general internists, gastroenterologists, cardiologists, endocrinologists and 
general surgeons, including gastrointestinal or breast surgeons, who registered for 
marketing research. Questions addressed their usage of CPGs in practice, education, 
and research, as well as their attitudes toward CPGs. We then investigated associa-
tions between usage and characteristics of the respondents. Results: We received 
responses from 1342 physicians, 1222 (91.1%) of whom were male (mean age (SD), 46.5 
(9.6) years). The proportion of respondents who always or often use CPGs in several 
practice settings, such as when providing explanations to patients based on CPGs, 
ranged from 27.7% to 54.6%. Among them, 822 respondents (61.3%) applied 1 to 4 CPGs, 
and 381 (28.4%) applied 5 to 9. Usage differed according to age group, subspecialty, 
and workplace. After multivariate adjustment, the mean probability (95% confidence 
interval) of a high usage of CPGs when providing explanations to patients was 65% 
(60% - 71%) and 40% (30% - 50%) for those aged < 40 y and ≥ 60 y, respectively, 44% 
(38% - 50%) for general internists, 65% (59% - 71%) for surgeons, and 51% (46% - 57%) 
and 65% (58% - 72%) for those working in clinics and university hospitals, respectively. 
Attitudes towards the trustworthiness and convenience of CPGs were associated 
with usage, although this was unable to explain all differences in usage among sub-
groups. ConClusions: A substantial proportion of Japanese physicians use CPGs 
in clinical practice. Age, subspecialty, and workplace were independently associated 
with CPG usage. This should be considered during the process of CPG implementation.
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objeCtives: The recent reforms and policy changes have increased the cost pres-
sures on all health care stakeholders, including clinical experts. In the past, clini-
the results did not cause an added value of the drug in this respective application. 
In seven cases the indirect comparison was declined due to a different comparator 
as determined by the G-BA. Three indirect comparisons were declined because of 
methodological deficiencies and another three indirect comparisons were declined 
because non-adjusted indirect comparisons were performed. ConClusions: The 
IQWiG only accepts adjusted indirect comparisons. The application of the correct 
methodology is necessary to gain valid results and shall not be questioned. The 
IQWiG approach is accurate with regard to contents and correct in a legal sense. 
However the procedure shows, that the external preconditions and methodologi-
cal requirements are demanding and almost impossible to fulfill. Main reason for 
denial is the divergence from the prespecified appropriate comparator set by the 
G-BA. To get back to the original aim of the early benefit assessment, a more realistic 
and reasonable determination of the appropriate comparator would be desirable.
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objeCtives: Policy makers of municipalities decided to adopt health technol-
ogy into the Brazilian Public Health System (SUS). This group met during national 
conferences. The last conference, “The XXVIII National Congress of Municipal 
Health Secretariats (CONASEMS)”, took place during June 11 to 14, 2012. The aim 
was describe the views of participants at the CONASEMS event regarding technol-
ogy assessment criteria for the Brazilian Public Health System (SUS). Methods: 
A survey applied at the Ministry of Health’s exhibition booth, June 11 to 14, 2012. 
Three variables were studied for the survey: “Participant Profile”, “Knowledge of 
Health Technology Assessment for Adoption by the SUS” and pre-selected criteria for 
assessing health technologies (where 1= most important and up to 9= least impor-
tant) Results: The survey encompassed 5.6% (244/4.328) of all conference partici-
pants. Of these, 43% represented policy makers; 35% health professionals and 22% 
others. Of the total amount of participants, 67% have little or average knowledge of 
HTA and 14% declared having no knowledge of the area. The values in the adoption 
of health technologies were ranked by delegates. The score of one was: evidence on 
patient safety, improved quality of life and patient survival, impact on the popula-
tion’s health. The score nine was: relationship between benefits and costs, health 
system costs and patient costs. ConClusions: Considering the results, the value 
related to criteria regarding quality of life and survival were the most important in 
detriment to cost criteria. It is important to involve the Brazilian Network for Health 
Technology Assessment (REBRATS) as an additional contribution to the application 
of the new Brazilian law regarding the incorporation of health technologies.
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objeCtives: Early benefit assessment pursuant to AMNOG was introduced to cut 
costs and illustrate the additional benefit of new pharmaceuticals including orphan 
drugs at launch in Germany. In this process orphan drugs have a special status. The 
EMA orphan drug designation implies the assumption that at least a not-quanti-
fiable additional benefit is set by law. However the extent of the additional benefit 
still has to be demonstrated by the manufacturer. Methods: By June 2013 seven 
orphan drug dossiers have been submitted and assessed. Only one product has been 
admitted an important additional benefit. Four substances had a minor additional 
benefit and two substances had a not-quantifiable additional benefit. Results: An 
additional benefit needs to be proven against a comparator. But the G-BA will not 
define an appropriate comparator as for non-orphan drugs. Instead, the assessment 
of orphan drugs is based on the pivotal trial; the comparator will be derived from 
this trial. Due to the early phase of pivotal trials in rare diseases, using a compara-
tor is not common. Furthermore, phase II trials often do not meet requirements in 
terms of evidence level requested: randomized controlled trials with large patient 
populations are unusual in orphan diseases as well as investigation of valid patient 
relevant endpoints or validated surrogate endpoints. ConClusions: The G-BA 
requirements for HTA assessments are drawn from phase III trials and demonstra-
tion of an additional benefit over an appropriate comparator, which also serves as 
price benchmark. The requirements derived for all newly launched products do not 
reflect orphan drug reality, which is indication and not agent based. In summary 
the EMA declaration of early admission of orphan drugs in phase II conflicts with 
the G-BA’s methodological requirements for the quantification of an additional 
benefit. In fact, manufacturers of orphan drugs face an additional barrier before 
launch in Germany.
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objeCtives: This paper constructs a composite index that is sufficiently compre-
hensive to rank the overall health status of Irish regions and sufficiently detailed to 
identify the principal sources of varying regional health status. Methods: We draw 
on the CSO (Central Statistics Office), PCRS (Primary Care Reimbursement Service) 
and IPH (Institute of Public Health) health and medicines databases to construct 
a composite index of the health status of the 8 HSE regions in Ireland in 2010. Our 
composite health index (CHI) has 6 component indices. Each maps the regional 
prevalence of major health conditions for which an ATC (Anatomical Therapeutic 
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significantly reduced by using the ETHICON SECURESTRAP™ Open fixation device 
compared with suture fixation of IPOM mesh. This shows promise of reducing open 
IPOM procedure time which may realize related patient benefits of reduced anesthe-
sia time, infection risks, costs etc. Also, reduction in surgical stress could potentially 
offer improvement in surgical performance – benefiting the surgeon, the patient 
and the health care system.
HealtH Care Use & PoliCy stUdies – regulation of Health Care sector
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Cost savinGs in tHe HUnGarian Care ManaGinG ProGraMMe
Ágoston I., Vajda R., Jankó-Király A., Lampek K., Boncz I.
University of Pécs, Pécs, Hungary
objeCtives: A pilot care managing programme was introduced in Hungary in 1999. 
The conceptual foundations of the Hungarian implementation of managed care is 
closer to what was called the GP fundholding in the UK than HMOs in the USA. The 
purpose of the study is to analyse the cost savings realized within the Hungarian 
care managing programme. Methods: The data derive from the financial data-
base of the Hungarian National Health Insurance Fund Administration (NHIFA) 
covering the period 1999-2007. We identified the annual cost savings realized by 
the Care Managing Organizations. The Hungarian CMOs was financed through 
a risk adjusted capitation fee and the health services covered by CMOs were 
defined in legal regulations. Cost saving was defined as the difference between 
the annual revenues (capitation fee) and expenditures (real utilization) of care 
managing organizations. Results: During the study period the total number of 
persons covered by the care managing programme increased from 1.5 % of the 
Hungarian population to its peak of 19.4 % in 2005. The cost saving of the care 
managing programme was 63138000 Hungarian Forint (HUF) or 249756 Euro (EUR) 
in 1999; 457662600 HUF (1759945 EUR) in 2000, 1109442300 HUF (4322246 EUR) in 
2001; 2710926900 HUF (11157503 EUR) in 2002; 1452041100 HUF (5727683 EUR) in 
2003, 3799000306 HUF (15094804 EUR) in 2004; 3709400000 HUF (14954510 EUR) in 
2005; 4964600000 HUF (18786048 EUR) in 2006 and 3669000000 HUF (14599437 EUR) 
in 2007. These amounts resulted in the following annual savings rate: 1999: 3.6%; 
2000: 10.4%; 2001: 6.5%; 2002: 8.7%; 2003: 3.4%; 2004: 4.0%; 2005: 2.1%; 2006: 2.9% and 
2007: 2.9%. ConClusions: With the development of the Hungarian care managing 
system, the average number of enrolees increased. Cost savings of Care Managing 
Organizations varied between 2.1-4.0 % during the mature period of this programme.
PHP199
systeMatiC review on tHe iMPaCts oF striCt PHarMaCeUtiCal PriCe 
Controls
Relakis J.1, Maniadakis N.1, Kourlaba G.2, Shen J.3, Holtorf A.P.4
1National School of Public Health, Athens, Greece, 2National and Kapodistrian University of 
Athens School of Medicine, Athens, Greece, 3Abbott, Basel, Switzerland, 4Health Outcomes 
Strategies LLC, Basel, Switzerland
objeCtives: To systematically review and synthesize published evidence on the 
impact of pharmaceutical price controls, such as price cuts, price caps, price freezes 
or international price referencing. Methods: A literature search was conducted 
in Medline, Scopus, Econlit, Web of Science and ABI/INFORM to identify relevant 
studies published in English to March 2013. Results: Forty-seven out of 3787 initial 
studies were included. Price caps and price reductions were most commonly studied 
in the literature, followed by reference pricing and price freezes. The evidence indi-
cates that price controls reduce company profits and have a detrimental effect on 
pharmaceutical research and development, pipeline productivity and investment. 
They may also inhibit, reduce or delay new product launches, increase parallel 
exports and diminish availability of generics due to disincentives and, hence, may 
reduce product availability, increase withdrawals and shortages. In terms of public 
expenditure about half of the studies indicate realized savings, but the other half 
indicate no effect or even increases in expenditure. In terms of effects on patients, 
studies indicate in the short term welfare gains due to lower cost and better access, 
but also losses due to drug shortages and availability issues. Long-term effects 
appear to be welfare losses due to reductions of discoveries, resulting from the 
disinvestment associated with the lower revenues. ConClusions: Effects of price 
controls are ambiguous in the case of pharmaceuticals. Price controls reduce drug 
acquisition cost and increase access in the short run. On the other hand, they may 
decrease patient welfare and access as they can cause product shortages, withdraw-
als and launch delays. Moreover, they may reduce the likelihood for new product dis-
coveries. Contrary to common beliefs, price controls not always reduce expenditure. 
Thus careful consideration is needed in designing drug price policies. Value based 
pricing approaches may be more effective alternatives compared to price cutting.
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objeCtives: Relationships between National/Regional Health care Systems (NHS) 
and pharmaceutical companies can and should be based on a cooperative venture, 
built on the expertise of each side, that best meets clearly defined public needs 
through the appropiate allocation of resources, risks and rewards, while preserv-
ing transparency and its independence. However, joint working can be difficult to 
initiate due to the number of parties involved and the lack of clear shared objec-
tives. Guidelines can be very useful to support the NHS/Pharmaceutical Partner’s 
commitment. To our knowledge, there are no such published guidelines in Spain. 
This first guidance in Spain was designed with the main aim of identifying and 
simplifying the initiation, the start-up phase and the remainder of joint working 
projects between the Catalan Heath System (CatSalut) and pharmaceutical com-
panies. Methods: A flowchart was designed to describe the standard steps and 
timelines suggested to start, implement, monitor and evaluate a Joint Working pro-
cal guidelines were developed independent of cost or economic considerations. 
However, increasingly, more clinical guidelines are mentioning cost concerns and 
referring to economic data in new recommendations. The objective of this study was 
to analyze trends in the use of health economic information for developing clinical 
guidelines. Methods: To understand trends in use of health economic information 
we conducted targeted search for clinical guidelines, expert recommendations, and 
consensus statements with specific mention of “cost” or “economic” or related terms. 
A systematic literature search was undertaken for the databases Pubmed, Google 
Scholar and Cochrane. The guidelines published between 2003-2012 were included. 
For guidelines which met the search criteria, data was collected for the name of the 
authors, indication, year of publication, country/region, and context of use of cost/eco-
nomic evidence. Results: Sixteen clinical guidelines published between 2003-2012 
met the inclusion criteria for specific mention of cost/economic evidence. More than 
50% of these guidelines were published between 2006-2012. For indication, 3 out of 
16 guidelines were for diabetes, while the rest were for different indications. In these 
16 guidelines “cost effectiveness” was mentioned 14 times, either referencing cost-
effectiveness data or to mention the importance of such data for selecting treatment 
options. The guidelines commonly cite high cost of disease or high economic burden 
as one of the considerations for developing new recommendations (11 out of 16). 
Another term that was commonly used by these guidelines was “cost-benefit,” which 
was mentioned 5 times in these guidelines. Notably, QALY was rarely mentioned (1 
out of 16 times) in these guidelines. ConClusions: This analysis suggests that some 
clinical experts groups are increasingly showing willingness to use and incorporate 
health economic information for developing new recommendations.
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objeCtives: To review all the reasons provided by the European Medicines Agency 
(EMA) to substantiate the need for revisions to or updates of disease-specific scien-
tific guidelines developed by the Committee for Medicinal Products for Human Use 
(CHMP). Methods: All the scientific guidelines issued by the CHMP were reviewed 
on the EMA’s website. The guidelines not focusing on disease-specific issues were 
not selected, i.e., guidelines listed in the following sections: Clinical Pharmacology 
and pharmacokinetics, General, Herbal Medicinal products, Information on medici-
nal products, and Radiopharmaceutical and diagnostic agents. Results: A total of 
182 disease-specific scientific guidelines were reviewed. The review identified 21 
concept papers developed with the intent of revision (11.5% of specific guidelines). 
The analysis of the concept papers revealed that four main reasons were claimed: 
1) Clarifications needed for pediatric development [10 concept papers: acute heart 
failure, asthma, Crohn’s disease, hepatitis C, hypertension, glucocorticoid-induced 
osteoporosis, irritable bowel syndrome (IBS), multiple sclerosis, pain, and ulcerative 
colitis); 2) Evolution in the field and treatments (n= 9); 3) Clarifications on endpoints 
identification and measurement (n= 7); and 4) Safety aspects (n= 6). For instance, 
in asthma, one of the critical aspects to be discussed regarding endpoints was “the 
need to reinforce the use of clinical measurements (symptoms) and patient-reported outcome 
measures to complement lung-function parameters.” In IBS, regulators asked that “An 
evaluation whether more clear recommendations as regards the use of certain 
scales or newly developed PROs can be made is also desirable.” ConClusions: The 
main reason for the EMA to revise disease-specific guidelines is the need for provid-
ing guidance in pediatric issues. This is in line with the introduction of Pediatric 
Investigation Plans (PIPs) by the European Commission in January 2007 to help 
ensure that medicines for children are included in the mainstream drug develop-
ment process in Europe.
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ventral Hernia rePair
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objeCtives: This study compared fixation time using ETHICON SECURESTRAP™ 
Open device to suture fixation of IPOM mesh in ventral/ incisional hernia repair. It 
also assesses surgeon-reported levels of task load experienced during the two fixa-
tion approaches. Methods: Nine surgeons inserted skirted mesh using IPOM tech-
nique on created incisional defects in live swine models. Each surgeon performed 
two suture (using their standard technique) and two ETHICON SECURESTRAP™ 
Open fixation procedures. The duration of fixation procedure starting from mesh 
preparation through the last firing or suture knot was recorded. Surgical work-
load was measured using the validated Surgery Task Load Index (SURG-TLX) 
questionnaire. Time savings and task load reduction were determined by the 
lower limit of the two-sided 95% confidence interval for the difference between 
suture fixation and ETHICON SECURESTRAP™ Open groups. Results: A total of 
38 IPOM fixation procedures were performed with equal numbers using suture 
and ETHICON SECURESTRAP™ Open. 89% reduction in mean fixation time was 
observed from suture to mechanical fixation with ETHICON SECURESTRAP™ Open 
[mean reduction: 34.9 minutes (SD: 17.9 minutes); p< 0.0001]. Similarly, 55% reduc-
tion in perceived overall workload was observed with SECURESTRAP™ Open com-
pared to suture fixation [mean reduction: 22.17 (SD: 15.12); p= 0.0003]. ETHICON 
SECURESTRAP™ Open demonstrated significantly lower ratings in five of the six ele-
ments of surgical task load, namely – Mental Demand, Physical Demand, Situational 
Stress, Task Complexity, and Temporal Demand [p< 0.05 for all] compared to suture 
fixation. ConClusions: Time for fixation and related surgical task load can be 
